Co-infection associated with SARS-CoV-2 and their management

Author:

Chavda Vivek P1,Patel Aayushi B2,Pandya Anjali3,Vora Lalitkumar K4,Patravale Vandana3,Tambuwala Zara M5,Aljabali Alaa AA6ORCID,Serrano-Aroca Ángel7ORCID,Mishra Vijay8ORCID,Tambuwala Murtaza M9ORCID

Affiliation:

1. Department of Pharmaceutics & Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, Gujarat, 380009, India

2. Pharmacy Section, LM College of Pharmacy, Ahmedabad, Gujarat, 380058, India

3. Department of Pharmaceutical Sciences & Technology, Institute of Chemical Technology, Mumbai, 400 019, India

4. School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, BT9 7BL, UK

5. College of Science, University of Lincoln, Brayford Campus, Lincoln, LN6 7TS, UK

6. Department of Pharmaceutics & Pharmaceutical Technology, Yarmouk University, Faculty of Pharmacy, Irbid, 566, Jordan

7. Biomaterials & Bioengineering Lab, Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, c/Guillem de Castro 94, Valencia, 46001, Spain

8. School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, India

9. Lincoln Medical School University of Lincoln, Brayford Campus, Lincoln, LN6 7TS, UK

Abstract

SARS-CoV-2 was discovered in Wuhan, China and quickly spread throughout the world. This deadly virus moved from person to person, resulting in severe pneumonia, fever, chills and hypoxia. Patients are still experiencing problems after recovering from COVID-19. This review covers COVID-19 and associated issues following recovery from COVID-19, as well as multiorgan damage risk factors and treatment techniques. Several unusual illnesses, including mucormycosis, white fungus infection, happy hypoxia and other systemic abnormalities, have been reported in recovered individuals. In children, multisystem inflammatory syndrome with COVID-19 (MIS-C) is identified. The reasons for this might include uncontrollable steroid usage, reduced immunity, uncontrollable diabetes mellitus and inadequate care following COVID-19 recovery.

Publisher

Future Science Ltd

Subject

Biotechnology

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3